Mirikizumab Improves Quality of Life in Patients With Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study

被引：0
|
作者：
Lee, Scott D. [1 ]
Vermeire, Severine [2 ]
Ungaro, Ryan C. [3 ]
Durand, Frederick [4 ]
Morris, Nathan [4 ]
Yu, Guanglei [4 ]
Vadhariya, Aisha [4 ]
Traxler, Kristina [4 ]
Fisher, Deborah A. [5 ]
Long, Millie D. [6 ]
机构：
[1] Univ Washington, Med Ctr, Digest Hlth Ctr, Seattle, WA USA
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Eli Lilly & Co, Indianapolis, IN USA
[5] Eli Lilly & Co, Raleigh, NC USA
[6] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001035112.50210.ab
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1436
引用
收藏
页码：S1031 / S1032
页数：2
相关论文
共 50 条
  • [31] Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study
    Rosh, Joel R.
    Turner, Dan
    Griffiths, Anne
    Cohen, Stanley A.
    Jacobstein, Douglas
    Adedokun, Omoniyi J.
    Padgett, Lakshmi
    Terry, Natalie A.
    O'Brien, Christopher
    Hyams, Jeffrey S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (11): : 1931 - 1942
  • [32] PHARMACOKINETICS OF USTEKINUMAB IN CHILDREN AND ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM UNISTAR, A PHASE 1 STUDY
    Adedokun, Omoniyi J.
    Hyams, Jeffrey S.
    Turner, Dan
    Griffiths, Anne M.
    Terry, Natalie A.
    Padgett, Lakshmi
    Jacobstein, Douglas
    O'Brien, Christopher D.
    Rosh, Joel R.
    GASTROENTEROLOGY, 2020, 158 (06) : S131 - S132
  • [33] Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn's disease
    Blumenstein, I.
    Torres, J.
    Ma, C.
    Lindsay, J. O.
    Ungaro, R.
    Thin, L.
    Lacerda, A. P.
    Anyanwu, S. I.
    Garrison, A.
    Ford, S.
    Louis, E.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : II000 - I1001
  • [34] Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn's disease: Results from induction and maintenance phase 3 trials
    Ghosh, S.
    Feagan, B.
    Parra, R. S.
    Lopes, S.
    Steinlauf, A.
    Kakuta, Y.
    Joshi, N.
    Lee, W. J.
    Remple, V.
    Lacerda, A. P.
    Zhou, Q.
    Xuan, S.
    Louis, E.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 560 - +
  • [35] UPADACITINIB IMPROVED FATIGUE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM INDUCTION AND MAINTENANCE PHASE 3 TRIALS
    Ghosh, Subrata
    Feagan, Brian G.
    Parra, Rogerio S.
    Lopes, Susana
    Steinlauf, Adam F.
    Kakuta, Yoichi
    Joshi, Namita
    Lee, Wan-Ju
    Remple, Valencia
    Lacerda, Ana P.
    Zhou, Qian
    Xuan, Si
    Louis, Edouard
    GASTROENTEROLOGY, 2023, 164 (06) : S1106 - S1106
  • [36] Impact of Mirikizumab Therapy on Histologic Measures of Intestinal Inflammation in a Phase 2 Study of Patients With Moderately- to Severely-Active Crohn's Disease
    Pai, Rish
    De Hertogh, Gert
    Reinisch, Walter
    Harpaz, Noam
    Feagan, Brian G.
    Agada, Noah
    Pollack, Paul
    Chan, Lai Shan
    Protic, Marijana
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S421 - S422
  • [37] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
  • [38] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
    Andrews, J. M.
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
  • [39] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S214 - S214
  • [40] Guselkumab improves health-related quality of life as measured by PROMIS-29 in participants with moderately to severely active Crohn's disease: Phase 3 GRAVITI study
    Sands, B.
    Danese, S.
    Cao, Q.
    Steinwurz, F.
    Kierkus, J.
    Han, C.
    Olurinde, M.
    Yang, Z.
    Merrall, E.
    Terry, N. A.
    Hart, A.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2102 - i2104
12345